Septerna Inc (SEPN) News & EventsSEPNNews & EventsSepterna Inc

Septerna Reports Q2 Revenue of $26.75M, Beating Consensus

Reports Q2 revenue $26.75M, consensus $19.22M. "We continue to make meaningful progress across our portfolio as we execute on our strategy to develop differentiated oral medicines targeting GPCRs," said Jeffrey Finer, Chief Executive Officer and Co-founder of Septerna. "We are advancing our Phase 1 study of SEP-479 and are very pleased with the observed clinical half-life, which is at the longer end of our preclinical estimates. This finding reinforces our confidence in the potential of SEP-479 as a differentiated, once-daily oral treatment for hypoparathyroidism, and we look forward to presenting SAD/MAD data in the first quarter of 2027. We are also advancing our broader portfolio by evaluating the next phase of development for SEP-631 in mast cell-driven diseases and progressing our TSHR program toward development candidate selection."

Septerna Reports Q1 Revenue of $26.52M, Exceeding Expectations

Reports Q1 revenue $26.52M, consensus $15.09M. "In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the initiation of our Phase 1 clinical trial for SEP-479," said Jeffrey Finer, chief executive officer and co-founder of Septerna. "These advances further validate our Native Complex Platform and its ability to efficiently generate differentiated oral small molecules against historically challenging GPCR targets. As our clinical programs continue to advance, we believe Septerna is increasingly well positioned to unlock the broad therapeutic potential of GPCR-targeted medicines for patients with significant unmet need."

Septerna Doses First Participants in SEP-479 Clinical Trial

Septerna announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose and multiple-ascending dose clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants.